Factors of vascular calcification in patients with type 2 diabetes mellitus on long-term dialysis

PURPOSE: Defining vascular calcification markers in patients on long-term hemodialysis (LTH) with type 2 diabetes mellitus (type 2 diabetes) and without type 2 diabetes.

MATERIALS AND METHODS: The study was conducted in 82 patients with chronic kidney disease (CKD) (51 men, 31 women) on LTH, of which 25 patients (10 men, 15 women) had type 2 diabetes and 57 people (33 men, 24 women) had no diabetes. All patients underwent evaluation of calcium-phosphate metabolism, control of intact PTH (iPTH), inorganic phosphorus, and total calcium. All patients were tested for the level of fibroblast growth factor-23 (FGF23) in blood serum using a multi-enzyme immunoassay kit, and the correlation between these parameters and the presence of vascular calcification was evaluated.

RESULTS: A correlation was found between the severity of vascular calcification and the calcium-phosphate metabolism. In the group with type 2 diabetes, there is a correlation between the level of FGF23, iPTH, inorganic phosphorus and vascular calcification. There is also a correlation between the time on LTH and the increase in the level of FGF23 in patients with type 2 diabetes.

CONCLUSION: We obtained data that can indicate a more pronounced change in the vascular wall in patients with type 2 diabetes on LTH in comparison with patients without diabetes mellitus on LTH, which allows to associate high cardiovascular mortality in patients with type 2 diabetes on LTH with accelerated development of vascular calcification.

type 2 diabetes mellitus, vascular calcification, long-term hemodialysis, fibroblast growth factor 23

1. Шестакова М.В. Сахарный диабет и хроническая болезнь почек: современная диагностика и лечение // Вестник Российской академии медицинских наук. — 2012. — Т. 67. — №1. — С. 45−49. [Shestakova MV. Diabetes mellitus and chronic kidney disease: modern diagnostics and treatment. Annals of the Russian academy of medical sciences. 2012;67(1):45−49. (In Russ.)] doi: https://doi.org/10.15690/vramn.v67i1.109

2. Iijima K, Hashimoto H, Hashimoto M, et al. Aortic arch calcification detectable on chest X-ray is a strong independent predictor of cardiovascular events beyond traditional risk factors. Atherosclerosis. 2010;210(1):137−144. doi: https://doi.org/10.1016/j.atherosclerosis.2009.11.012

3. Seliger SL. Stroke in ESRD: The other cardiovascular disease. Am J Kidney Dis. 2009;54(3):403−405. doi: https://doi.org/10.1053/j.ajkd.2009.04.009

4. Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant. 2012;27:3072–3081. doi: https://doi.org/10.1093/ndt/gfs259

5. Mendoza JM, Isakova T, Cai X, et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 2017;91(3):711−719. doi: https://doi.org/10.1016/j.kint.2016.10.021

6. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132(2):245−250. doi: https://doi.org/10.1016/s0021-9150(97)00106-8

7. Милованова Л.Ю., Козловская Л.В., Маркина М.М., и др. Морфогенетические белки — фактор роста фибробластов-23 и Клото в сыворотке крови больных с хронической болезнью почек // Клиническая медицина. — 2015. — Т. 93. — №12. — С. 32−38. [Milovanova LY, Kozlovskaya LV, Markina MM, et al. Morphogenetic proteins — fibroblast growth factor and Klotho, in the sera of patients with chronic renal disease. Klinicheskaia meditsina. 2015;93(12):32−38. (In Russ.)]

8. Tonelli M, Muntner P, Lliod A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a populationlevel cohort study. Lancet. 2012;380:807–814. doi: https://doi.org/10.1016/s0140-6736(12)60572-8

9. Ветчинникова О.Н. Гиперпаратиреоз при хронической болезни почек // Эффективная фармакотерапия. — 2013. — №46. — С. 26−39. [Vetchinnikova ON. Hyperparathyroidism in chronic kidney disease. Effective pharmacotherapy. 2013;(46):26−39. (In Russ.)]

10. Сабодаш А.Б., Салихова К.А., Макарова О.В., и др. Коррекция гиперфосфатемии у пациентов на гемодиализе: опыт одного центра и анализ возможностей // Нефрология и диализ. — 2018. — Т. 20. — №4. — С. 366−377. [Sabodash AB, Salikhova KA, Makarova OV, et al. Hyperphosphatemia correction in hemodialysis patients. A single center study and perspective analysis. Nephrology and dialysis. 2018;20(4):366−377. (In Russ.)] doi: https://doi.org/10.28996/2618-9801-2018-4-366-377

11. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205(2):385−390. doi: https://doi.org/10.1016/j.atherosclerosis.2009.01.001

12. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009;24(10):3125−3131. doi: https://doi.org/10.1093/ndt/gfp205

13. Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011;6:2871–2878. doi: https://doi.org/10.2215/cjn.02740311

14. Добронравов В.А. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho // Нефрология. — 2011. — №4. — С. 11−20. [Dobronravov VA. Current view on the pathophysiology of hyperparathyroidism: role of fibroblast growth factor 23 and Klotho. Nephrology. 2011;(4):11−20. (In Russ.)]

15. Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017;37(2):191–204. doi: https://doi.org/10.1161/ATVBAHA.116.306256

16. Новикова М.С., Руденко Т.Е., Котяшкова О.М., Анциферов М.Б. Минерально-костные нарушения у пациентов с сахарным диабетом и хронической болезнью почек // Эффективная фармакотерапия. — 2013. — №46. — С. 46−52. [Novikova MS, Rudenko MS, Kotyashkova OM, Antsiferov MB. Mineral and bone disorder in patients with diabetes and chronic kidney disease. Effective pharmacotherapy. 2013;(46):46−52. (In Russ.)]

17. Freedman BI, Divers J, Russell GB, et al. Plasma FGF23 and calcified atherosclerotic plaque in African americans with Type 2 diabetes mellitus. Am J Nephrol. 2015;42(6):391−401. doi: https://doi.org/10.1159/000443241

18. Tamei N, Ogawa T, Ishida H, et al. Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patientson chronic hemodialysis. Atherosclerosis Thrombosis. 2011;18(3):217−223. doi: https://doi.org/10.5551/jat.5595

19. Мокрышева Н.Г., Маганева И.С. Минерально-костные нарушения у пациентов с хронической болезнью почек и сахарным диабетом: реальные возможности кардио- и нефропротекции // Медицинский совет. — 2018. — №4. — С. 60−65. [Mokrysheva NG, Maganeva IS. Mineral-bone disorders in patients with chronic kidney disease and diabetes mellitus: the real possibilities of cardio and nephroprotection. Medicinsky sovet. 2018;(4):60−65. (In Russ.)]